Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Peptide Research News November 2026 Roundup: Technology and Delivery Comparison

Mitochondrial-targeting (SS-31 analogs) Cardiolipin binding, cristae stabilization Subcutaneous injection FDA-approved (Nov 2026) Blood-brain barrier penetration previously thought impossible First mitochondrial peptide to achieve CNS therapeutic levels. Parad

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Mitochondrial-targeting (SS-31 analogs)
  • Cardiolipin binding, cristae stabilization
  • Subcutaneous injection
  • FDA-approved (Nov 2026)
  • Blood-brain barrier penetration previously thought impossible
  • First mitochondrial peptide to achieve CNS therapeutic levels. Paradigm shift for neurodegenerative treatment
  • Thymosin derivatives (thymosin-alpha-1)
  • T-cell receptor diversity restoration, thymic reactivation
  • EMA conditional approval
  • Requires twice-weekly dosing due to 8-hour half-life
  • Validated surrogate endpoint (TCR clonality) enables accelerated approval for aging-related immune decline
  • GLP-1/GIP dual agonists (tirzepatide, mazdutide)
  • Incretin receptor agonism, hepatic GIP signaling
  • Multiple FDA approvals 2023–2026
  • Weekly dosing achievable with PEGylation or albumin binding
  • Dual-agonism drives fibrosis regression in NASH. Monotherapy cannot replicate
  • GLP-1/glucagon dual agonists (survodutide)
  • Incretin + hepatic fatty acid oxidation
  • Phase 2 complete, Phase 3 enrollment
  • Higher nausea rates limit tolerability during titration
  • 18.6% weight loss exceeds tirzepatide but GI side effects may restrict real-world adherence
  • HGF potentiators (dihexa)
  • c-Met receptor activation, dendritic spine formation
  • Oral administration
  • Phase 2b cognitive trials
  • First-pass hepatic metabolism reduces CNS bioavailability
  • Oral bioavailability solves adherence problem for chronic cognitive decline. Major advantage over injectables
  • Neurotrophic mixtures (cerebrolysin)
  • BDNF-like activity, calpain inhibition
  • Intravenous infusion
  • Phase 3 stroke trials
  • Requires daily IV administration for 21 days
  • Validated neuroprotection in acute stroke with MRI-confirmed infarct reduction. Logistics limit adoption

Related resources

More comparisons